Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer

ESMO, hepatocellular carcinoma, gastric cancer, prostate cancer

The following ESMO Clinical Practice Guidelines have been recently updated with new treatment recommendations for the ESMO Clinical Practice Guidelines on Hepatocellular Carcinoma, Cancer of the Pancreas, Soft Tissue and Visceral Sarcomas, Cancer of the Prostate and Gastric Cancer.

Jun 6^th • 2 mins read

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

quality randomized studies, ESMO-MCBS, drug approval

The approval of new cancer drugs by the FDA and EMA is primarily based on positive results from well-designed randomized phase III clinical trials (RCTs). Not all RCTs are analyzed to support drug approval recommendations, highlighting the need for scales to evaluate RCT quality and clinical…

Feb 11^th • 3 mins read

The evolving landscape of precision medicine in primary liver cancer

liver cancer, personalized care, precision medicine

The field of oncology and cancer research is changing. As our understanding of the underlying biology of the disease improves, the one-size-fits-all treatment model has been exposed as inadequate. PLC is among the hardest to treat malignancies and as such carries one of the worst prognoses. While th…

Mar 29^th • 3 mins read